Kenta Kobayashi

Kenta Kobayashi

Auto-generated profile, based on publicly available information

Kenta Kobayashi

Department of Dermatology Keio University School of Medicine Tokyo Japan

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 July 2018 in The Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
KKKenta Kobayashi
Kenta Kobayashi
KTKeiji Tanese
Keiji Tanese
AKAkiharu Kubo
Akiharu Kubo
NMNaoko Matsumoto‐Mochimaru
Naoko Matsumoto‐Mochimaru
ASAya Sasaki
Aya Sasaki
NUNoriko Umegaki‐Arao
Noriko Umegaki‐Arao

12 March 2019 in The Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
KKKenta Kobayashi
Kenta Kobayashi
YKYuichi Kurihara
Yuichi Kurihara
JYJun Yamagami
Jun Yamagami
JIJumpei Ito
Jumpei Ito
HSHaruko Shima
Haruko Shima
TOTakeshi Ouchi
Takeshi Ouchi

31 December 2019 in Journal of Cutaneous Pathology
Verified
Journal Article
Closed access
PDF file
KKKenta Kobayashi
Kenta Kobayashi
TYTomoaki Yokoyama
Tomoaki Yokoyama
YMYoko Masuda
Yoko Masuda
IHIchiro Hashimoto
Ichiro Hashimoto
SAShin‐Ichi Ansai
Shin‐Ichi Ansai

11 November 2024 in The Journal of Dermatology
Verified
Journal Article
Open access
TATakeya Adachi
Takeya Adachi
TMTomoya Matsui
Tomoya Matsui
UOUtako Okata‐Karigane
Utako Okata‐Karigane
CTChiaki Takahashi
Chiaki Takahashi
UTUmi Tahara
Umi Tahara
HTHayato Takahashi
Hayato Takahashi
Immune checkpoint inhibitors (ICIs), such as pembrolizumab (PEM), are widely recognized for their antitumor efficacy, but they can also lead to various cutaneous adverse events (CAEs). While most CAEs can be managed with topical corticosteroids, severe cases may necessitate halting immunotherapy. The incidence of severe CAEs is notably higher in combination therapies involving ICIs than in monotherapies, emphasizing the need for stringent, long‐term management strategies. This includes potential modifications or discontinuations of the combination therapy. PEM, when added to the conventional paclitaxel + cisplatin (or carboplatin) ± bevacizumab regimen, has shown significant improvements in overall and progression‐free survival for patients with Stage IVB metastatic or locally uncontrolled recurrent cervical cancer. This case series retrospectively examined the incidence and management of CAEs in 19 female patients treated with this combination therapy between October 2022 and May 2023. Four patients exhibiting CTCAE grade 3 were identified. The four cases of severe CAEs involved erythema multiforme after the initial course of PEM combination chemotherapy. Notably, three patients experienced immediate hypersensitivity reactions, including anaphylaxis, during subsequent treatments. This observation underscores the necessity for rigorous dermatological monitoring of patients undergoing PEM combination chemotherapy. Such vigilance is crucial for early detection of adverse reactions and timely adjustment of treatment regimens, thereby enhancing patient safety.

6 July 2023 in Australasian Journal of Dermatology
Verified
Journal Article
Open access
KHKanako Hashimoto
Kanako Hashimoto
KKKenta Kobayashi
Kenta Kobayashi
YNYoshio Nakamura
Yoshio Nakamura
YYYuriko Yukino
Yuriko Yukino
GTGonogi Tsuji
Gonogi Tsuji
MAMasayuki Amagai
Masayuki Amagai